Abbott

Abbott 3Q09

3Q Revenues: $7.8 billion (+4%)

3Q Earnings: $1.5 billion (+37%)

YTD Revenues: $22.0 billion (+2%)

YTD Earnings: $4.2 billion (+26%)

Comments: Pharma revenues for 3Q09 were $4.1 billion, a 2% drop from last year. Currency fluctuation accounted for a 6% shortfall. Pharma sales for YTD were $11.6 billion, down 4% (with a 7% hit from currency). Pharma sales were led by Humira, which posted sales of $1.5 billion (+24%) in 3Q09 and $3.8 billion (+21%) YTD. Depakote sales plummeted due to generic competition, falling 71% to $92 million in 3Q09 and $324 million YTD. Earnings this quarter got a boost from a favorable patent settlement for a stent.